Efficacy and safety of daratumumab-based quadruplet therapy vs…
Multiple myeloma (MM) is the second most common hematologic malignancy worldwide. Recent therapeutic innovations, including the addition of daratumumab to standard regimens, have shown promising improvements in patient outcomes.
- Lab
- Preclinical
- Early trials
- Late trials
- In practice
Intestinal Lymphangioma With Extensive Secondary Lymphangiectasia…
Intestinal lymphangiectasia is a rare disorder characterized by dilated lymphatic vessels in the gastrointestinal tract, typically presenting with protein-losing enteropathy. Adult-onset cases with severe gastrointestinal bleeding are exceptionally rare.
Novel or significantly improved treatmentAdjuvant Osimertinib in Resected EGFR-Mutated Stage IB-IIIA Non-Small…
In ADAURA, adjuvant osimertinib improved DFS and OS versus placebo in resected EGFR-mutated stage IB-IIIA NSCLC. We report a post hoc exploratory analysis of long-term OS post-adjuvant treatment completion.
Promising but preliminaryComprehensive In Silico Analysis Identifies MSTO1 and LIG1 as…
Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and remains a major cause of cancer-related mortality worldwide. Its poor clinical outcomes are largely attributed to late-stage diagnosis and the limited accuracy of currently available diagnostic and prognostic biomarkers.
Promising but preliminaryMolecular events underlying sarcoma development and progression
Sarcomas are a very rare (<1% solid tumors) and highly heterogeneous group of malignant neoplasms with over 100 subtypes. The complexity and rarity of this disease pose serious troubles with differential diagnosis with the use of traditional methods (histology and immunohistochemistry); hence, there is more and more interest in the genetic background of sarcoma development and prognosis in search for genetic markers that might allow the improvement of the diagnostic process, disease prognosis, and monitoring.